Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Guggenheim Reiterates Buy on Centessa Pharmaceuticals, Maintains $28 Price Target

Author: Benzinga Newsdesk | October 06, 2025 08:14am
Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price target.

Posted In: CNTA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist